Incyte Corporation (0J9P)
LSE
Closed
Aug 24, 2026
Day's Range
124.7852 wk Range
81.50Overview - 0J9P - Incyte Corporation
Key Statistics
Valuation
Enterprise Value
21.58B
P/E (Trailing)
‪0.30‬
Price / Book
‪4.07‬
EV / EBITDA
‪11.11‬
Profitability
Profit Margin
‪27.70%‬
Operating Margin
‪41.89%‬
Return on Assets
‪16.83%‬
Return on Equity
‪30.66%‬
Ownership
Shares Outstanding
212.80M
Float
170.74M
Held by Insiders
‪1.83%‬
Held by Institutions
‪103.83%‬
Price stats
Beta
‪0.76‬
50-Day Avg
‪60.56‬
200-Day Avg
‪60.39‬
Market Cap - 0J9P - Incyte Corporation
Peers - 0J9P - Incyte Corporation
Peer Comparison
Compared with companies in Biotechnology listed on LSE.
- 0J9PLSEIncyte Corporation27.37BMarket Cap+33.54%52-week change0.31P/E (Trailing)‪27.70%‬Profit Margin
- 0MGBLSEGenmab A/S173.69BMarket Cap+27.59%52-week change30.65P/E (Trailing)‪29.01%‬Profit Margin
- 0QZULSEVertex Pharmaceuticals Incorporated140.31BMarket Cap+29.11%52-week change0.58P/E (Trailing)‪34.99%‬Profit Margin
- 0R2MLSERegeneron Pharmaceuticals, Inc.90.49BMarket Cap+30.71%52-week change0.12P/E (Trailing)‪27.86%‬Profit Margin
- 0A45LSEModerna, Inc.66.31BMarket Cap+81.03%52-week change55.34P/E (Trailing)‪11.32%‬Profit Margin
- 0QW0LSEargenx SE52.61BMarket Cap+34.75%52-week change42.42P/E (Trailing)‪-47.51%‬Profit Margin
- 0NZTLSEUCB SA44.92BMarket Cap+9.88%52-week change127.93P/E (Trailing)‪6.45%‬Profit Margin
Profile Summary - 0J9P - Incyte Corporation
About
Incyte Corporation is a biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics targeting hematology, oncology, inflammation, and autoimmunity. Its portfolio features key products such as JAKAFI (ruxolitinib), approved for intermediate or high-risk…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
